The primary purpose of the study is to help answer the following research questions, and not
to provide treatment for Rheumatoid Arthritis (RA):
- The safety of LY2439821 and any side effects that might be associated with it.
- Whether LY2439821 can help participants with active RA.
- How much LY2439821 should be given to participants.
A Study in Participants With Moderate to Severe Psoriasis
Completed
Eli Lilly and Company
Phase 2
2010-04-01
The primary purpose for this study is to help answer the following research questions
- The safety of ixekizumab (LY2439821) and any side effects that might be associated with
it.
- Whether ixekizumab can help participants with Psoriasis.
- How much ixekizumab should be given to participants.
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
Completed
Eli Lilly and Company
Phase 3
2012-05-18
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to
etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
Completed
Eli Lilly and Company
Phase 3
2012-07-28
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to
etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
Completed
Eli Lilly and Company
Phase 3
2013-03-01
The purpose of this study is to evaluate the serum concentration of ixekizumab after
administration using either prefilled syringe or auto-injector in participants with moderate
to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety
extension.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
